Toxicological Profiling of Engineered Nanomaterials (ENMs) in the MPS (RES)
Toxicological Profiling of Engineered Nanomaterials (ENMs) in the MPS (RES)
批准号:
9769728
负责人:
Andre Elias Nel
金额:
$41.8万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-01 至 2021-08-31
关键词:
3-DimensionalAcuteAddressAdoptive TransferAnimalsAntigen-Presenting CellsAntigensAutophagocytosisBiochemicalBiodistributionBlood CirculationCategoriesCell membraneCell physiologyCellsCellular StructuresChronicCoculture TechniquesCollaborationsDataDecision AnalysisDecision MakingDendritic CellsDevelopmentDiseaseEngineeringExposure toGoalsHazard AssessmentHazardous SubstancesHepatocyteHepatotoxicityHumanImageImmune systemIn VitroInflammasomeInflammationInjectionsInjuryIntravenousKnowledgeKupffer CellsLibrariesLinkLiverLungMediatingMethodsMissionModelingMolecularMononuclearMusOrganOutcomeOxidation-ReductionOxidative StressPathway interactionsPeptidesPhagocytesPharmaceutical PreparationsPhysiologicalPropertyPublic HealthReporter GenesResearchResearch PersonnelReticuloendothelial SystemRiskRisk AssessmentSafetyShapesSkinStructure-Activity RelationshipSurfaceSystemT-LymphocyteTestingTherapeuticTissuesToxic effectToxicity TestsToxicologyTransgenic AnimalsUnited States National Institutes of HealthWorkadverse outcomeantigen challengebasebody systemcombinatorialdesigndisabilityexperiencehazardimmunotoxicityin vivoinnovationmacrophagenanonanomaterialsnanoparticle deliverynew technologynovelpredictive modelingpreservationprotective effectresponsesafety assessmentscreeningtherapeutic nanoparticles
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
There is a fundamental gap in understanding the impact of engineered nanomaterials (ENM) on the
mononuclear phagocyte system (MPS), including Kupffer cells (KC) in the liver and antigen-presenting
dendritic cells (DC) in the immune system. Our long-term goal is to develop a predictive 21st century
toxicological platform for ENM safety assessment that is premised on cellular and organotypic cultures for high
content screening, in which we will use adverse outcome pathways (AOPs) to derive structure-activity
relationships (SARs) for toxicological profiling and decision analysis on consortium-provided ENMs. The
overall objective is to use our mechanistic and high content screening approaches to perform hazard ranking,
tiered risk assessment, and SAR analysis that link ENM physicochemical properties to AOPs in KC and DC,
which is then used as the basis of in vivo predictions of the adverse impact on the liver and immune system.
Our central hypothesis is that linkage of the ENM properties to molecular and pathophysiological alterations in
the MPS will allow a mechanistic and high throughput approach for predicting the hazardous impact of ENMs
on the MPS. The rationale of the proposed research is that the development of predictive and alternative
testing platforms, including organotypic and cell co-culture models, will allow expedited risk assessment and
categorization of broad ENM categories. Guided by our extensive experience for predictive toxicological
modeling, we propose to explore the impact of the consortium-provided ENMs on the MPS in three specific
aims: Aim 1: To use mechanistic, high content screening for hazard ranking and toxicological profiling of a
diverse range of ENMs in KC and DC for SAR analysis and predictive toxicological profiling that can be used to
plan studies in liver micro-tissues and animals. Aim 2: To use organotypic 3-D liver models, and limited in vivo
toxicity assessment, imaging and biodistribution studies for toxicological profiling of a diverse range of related
to toxicological injury pathways at the KC/hepatocyte interface and the liver of transgenic animals that express
reporter genes (e.g., NF-κB). Aim 3: To use an antigen-specific (OVA peptide) dendritic and T-cell co-culture
system and adoptive transfer in mice for toxicological and immunotoxicological profiling of a diverse range of
ENMs, prior screened in Aim 1. Our approach is innovative, because of the substantive departure from the
current status quo, where descriptive single agent toxicity testing will be replaced by rapid throughput, high
content, and AOP-based predictive toxicological approaches for ENM effects on the MPS. The proposed
research is significant because we will introduce mechanisms-based HTS approaches that can be used to link
ENMs physicochemical properties to cellular and molecular response profiles for hazard profiling of
intravenous injected ENMs. Not only will this provide a platform for expedited safety assessment of ENMs, but
will also form the basis of extensive collaboration with the consortium, where predictive modeling can be used
to study exposure systems such as the lung, GIT and the skin.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
-
批准号:10187533
-
项目类别:
-
资助金额:$55.31万
-
财政年份:2020
-
负责人:Andre Elias Nel
-
依托单位:
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
-
批准号:10058189
-
项目类别:
-
资助金额:$55.31万
-
财政年份:2020
-
负责人:Andre Elias Nel
-
依托单位:
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
-
批准号:10417161
-
项目类别:
-
资助金额:$52.93万
-
财政年份:2020
-
负责人:Andre Elias Nel
-
依托单位:
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
-
批准号:10654816
-
项目类别:
-
资助金额:$51.28万
-
财政年份:2020
-
负责人:Andre Elias Nel
-
依托单位:
Toxicological Profiling of Engineered Nanomaterials (ENMs) in the MPS (RES)
-
批准号:9186735
-
项目类别:
-
资助金额:$41.8万
-
财政年份:2016
-
负责人:Andre Elias Nel
-
依托单位:
Toxicological Profiling of Engineered Nanomaterials (ENMs) in the MPS (RES)
-
批准号:9341321
-
项目类别:
-
资助金额:$41.8万
-
财政年份:2016
-
负责人:Andre Elias Nel
-
依托单位:
Center for Nanobiology and Predictive Toxicology
-
批准号:8393965
-
项目类别:
-
资助金额:$7.56万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Center for Nanobiology and Predictive Toxicology
-
批准号:8464703
-
项目类别:
-
资助金额:$105.49万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
-
批准号:8206804
-
项目类别:
-
资助金额:$39.36万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Administrative Core
-
批准号:8067636
-
项目类别:
-
资助金额:$6.89万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Center for Nanobiology and Predictive Toxicology
-
批准号:8147701
-
项目类别:
-
资助金额:$109.06万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Center for Nanobiology and Predictive Toxicology
-
批准号:8274480
-
项目类别:
-
资助金额:$107.03万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
-
批准号:8795269
-
项目类别:
-
资助金额:$2.28万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
-
批准号:8605676
-
项目类别:
-
资助金额:$6.46万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Project 2: Relating ENM Physicochemical Properties to Mechanism-Based Pulmonary T
-
批准号:8067631
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
-
批准号:8537555
-
项目类别:
-
资助金额:$4.52万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
-
批准号:8410038
-
项目类别:
-
资助金额:$36.93万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
-
批准号:8605860
-
项目类别:
-
资助金额:$38.05万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
-
批准号:7795767
-
项目类别:
-
资助金额:$42.07万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Center for Nanobiology and Predictive Toxicology
-
批准号:8016739
-
项目类别:
-
资助金额:$114.43万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
海外基金